| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 52 | 2024 | 15951 | 1.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 28 | 2023 | 5582 | 1.240 |
Why?
|
| Conservation of Natural Resources | 2 | 2015 | 16 | 1.030 |
Why?
|
| Lung Neoplasms | 39 | 2023 | 12045 | 0.940 |
Why?
|
| Coleoptera | 1 | 2024 | 19 | 0.920 |
Why?
|
| Heteroptera | 1 | 2024 | 14 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 16751 | 0.860 |
Why?
|
| Selenium | 5 | 2017 | 51 | 0.820 |
Why?
|
| Paclitaxel | 14 | 2024 | 2114 | 0.780 |
Why?
|
| Composting | 1 | 2021 | 1 | 0.770 |
Why?
|
| Salmonella enterica | 1 | 2021 | 12 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2023 | 3429 | 0.670 |
Why?
|
| Sputum | 3 | 2017 | 156 | 0.610 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2022 | 632 | 0.600 |
Why?
|
| Carboplatin | 7 | 2021 | 890 | 0.580 |
Why?
|
| Hydrazines | 4 | 2021 | 213 | 0.540 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 88 | 0.520 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 96 | 0.510 |
Why?
|
| Middle Aged | 108 | 2024 | 90569 | 0.500 |
Why?
|
| Aged | 95 | 2024 | 73640 | 0.500 |
Why?
|
| Ipilimumab | 4 | 2024 | 772 | 0.490 |
Why?
|
| Everolimus | 5 | 2021 | 436 | 0.480 |
Why?
|
| Dietary Supplements | 3 | 2013 | 552 | 0.460 |
Why?
|
| Circulating Tumor DNA | 4 | 2022 | 277 | 0.450 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2024 | 1385 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 8 | 2015 | 4470 | 0.410 |
Why?
|
| Adult | 85 | 2024 | 82073 | 0.410 |
Why?
|
| Humans | 151 | 2024 | 270804 | 0.400 |
Why?
|
| Biomarkers, Tumor | 11 | 2023 | 10731 | 0.390 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2021 | 1338 | 0.390 |
Why?
|
| Female | 104 | 2024 | 148936 | 0.390 |
Why?
|
| Male | 103 | 2024 | 128520 | 0.380 |
Why?
|
| Bevacizumab | 4 | 2023 | 967 | 0.380 |
Why?
|
| Antineoplastic Agents | 19 | 2024 | 14639 | 0.380 |
Why?
|
| Maximum Tolerated Dose | 11 | 2024 | 1329 | 0.370 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2009 | 347 | 0.360 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2017 | 232 | 0.360 |
Why?
|
| Agriculture | 2 | 2024 | 40 | 0.350 |
Why?
|
| Boron Compounds | 2 | 2021 | 72 | 0.350 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1404 | 0.350 |
Why?
|
| Triazoles | 4 | 2021 | 629 | 0.350 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2020 | 1536 | 0.340 |
Why?
|
| Ecosystem | 2 | 2024 | 115 | 0.330 |
Why?
|
| Biodiversity | 3 | 2021 | 95 | 0.320 |
Why?
|
| Aged, 80 and over | 36 | 2024 | 31117 | 0.320 |
Why?
|
| DNA Methylation | 2 | 2017 | 2769 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 10409 | 0.310 |
Why?
|
| Glycine | 2 | 2021 | 322 | 0.310 |
Why?
|
| Sulfonamides | 4 | 2020 | 1943 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2021 | 360 | 0.280 |
Why?
|
| Mutation | 16 | 2024 | 15922 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2023 | 4966 | 0.280 |
Why?
|
| Treatment Outcome | 32 | 2024 | 33859 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2020 | 1270 | 0.280 |
Why?
|
| Leiomyosarcoma | 2 | 2016 | 253 | 0.280 |
Why?
|
| Histone Deacetylase Inhibitors | 4 | 2023 | 617 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2020 | 6259 | 0.270 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2010 | 193 | 0.270 |
Why?
|
| Sarcoma | 3 | 2023 | 1851 | 0.270 |
Why?
|
| Vomiting | 3 | 2021 | 359 | 0.270 |
Why?
|
| Young Adult | 23 | 2023 | 22255 | 0.260 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 930 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 3656 | 0.260 |
Why?
|
| Nausea | 3 | 2023 | 537 | 0.250 |
Why?
|
| Sirolimus | 3 | 2020 | 830 | 0.250 |
Why?
|
| Fatigue | 4 | 2023 | 1292 | 0.250 |
Why?
|
| Pyrimidines | 5 | 2020 | 3671 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2021 | 5606 | 0.240 |
Why?
|
| Carcinoma, Small Cell | 4 | 2020 | 426 | 0.240 |
Why?
|
| Farms | 1 | 2024 | 3 | 0.230 |
Why?
|
| Neoplasm Staging | 21 | 2019 | 14037 | 0.230 |
Why?
|
| Immunotherapy | 5 | 2021 | 3561 | 0.230 |
Why?
|
| Chemoprevention | 2 | 2013 | 251 | 0.230 |
Why?
|
| Vitamin E | 3 | 2011 | 132 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 4 | 2023 | 2659 | 0.230 |
Why?
|
| Plants | 1 | 2024 | 64 | 0.230 |
Why?
|
| Constipation | 2 | 2016 | 189 | 0.220 |
Why?
|
| Benzoxazoles | 1 | 2024 | 40 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2017 | 375 | 0.220 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2021 | 398 | 0.210 |
Why?
|
| Mucositis | 1 | 2023 | 149 | 0.210 |
Why?
|
| Osteosarcoma | 2 | 2023 | 951 | 0.210 |
Why?
|
| Melanoma | 7 | 2021 | 5601 | 0.210 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 289 | 0.210 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2018 | 1336 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2021 | 5053 | 0.200 |
Why?
|
| Cisplatin | 13 | 2010 | 2509 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2023 | 74 | 0.200 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 2356 | 0.190 |
Why?
|
| Manure | 1 | 2021 | 3 | 0.190 |
Why?
|
| Radiosurgery | 2 | 2024 | 1389 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2024 | 2363 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 6 | 2017 | 2396 | 0.190 |
Why?
|
| Fertilizers | 1 | 2021 | 5 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2023 | 211 | 0.190 |
Why?
|
| Soil Microbiology | 1 | 2021 | 16 | 0.190 |
Why?
|
| Taxoids | 6 | 2024 | 1019 | 0.190 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 871 | 0.190 |
Why?
|
| Liquid Biopsy | 2 | 2022 | 167 | 0.190 |
Why?
|
| Exanthema | 2 | 2022 | 213 | 0.190 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 37 | 0.190 |
Why?
|
| Soil | 1 | 2021 | 56 | 0.180 |
Why?
|
| Medical Laboratory Science | 1 | 2000 | 23 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2023 | 1905 | 0.180 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1098 | 0.180 |
Why?
|
| Clostridium | 1 | 2020 | 26 | 0.180 |
Why?
|
| Neoplasm Metastasis | 13 | 2021 | 5332 | 0.180 |
Why?
|
| Spores, Bacterial | 1 | 2020 | 46 | 0.180 |
Why?
|
| Anorexia | 1 | 2021 | 143 | 0.180 |
Why?
|
| Adenine | 1 | 2024 | 674 | 0.180 |
Why?
|
| Granulosa Cell Tumor | 1 | 2021 | 81 | 0.180 |
Why?
|
| Nitroimidazoles | 1 | 2021 | 104 | 0.180 |
Why?
|
| Antiemetics | 1 | 2021 | 122 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2024 | 1580 | 0.180 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 199 | 0.170 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 3841 | 0.170 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2023 | 318 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 381 | 0.170 |
Why?
|
| Karyopherins | 1 | 2021 | 134 | 0.170 |
Why?
|
| Neutropenia | 2 | 2023 | 1006 | 0.170 |
Why?
|
| Quinolones | 1 | 2021 | 163 | 0.170 |
Why?
|
| Skin Neoplasms | 4 | 2018 | 4900 | 0.170 |
Why?
|
| Prognosis | 19 | 2021 | 22533 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2014 | 616 | 0.170 |
Why?
|
| Vascular Neoplasms | 1 | 2000 | 112 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 1101 | 0.170 |
Why?
|
| Tomography, Emission-Computed | 1 | 2000 | 334 | 0.160 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 361 | 0.160 |
Why?
|
| Gene Amplification | 1 | 2022 | 764 | 0.160 |
Why?
|
| Ovarian Neoplasms | 4 | 2022 | 4810 | 0.160 |
Why?
|
| Drug Administration Schedule | 12 | 2019 | 3533 | 0.160 |
Why?
|
| Naltrexone | 2 | 2016 | 99 | 0.160 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 467 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 2659 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 1587 | 0.160 |
Why?
|
| Forests | 1 | 2018 | 3 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 202 | 0.160 |
Why?
|
| Trees | 1 | 2018 | 15 | 0.160 |
Why?
|
| Cholangiocarcinoma | 1 | 2024 | 506 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 183 | 0.160 |
Why?
|
| Droughts | 1 | 2018 | 11 | 0.160 |
Why?
|
| Laryngeal Neoplasms | 4 | 1992 | 530 | 0.160 |
Why?
|
| Quinazolines | 3 | 2021 | 956 | 0.160 |
Why?
|
| Survival Analysis | 13 | 2020 | 9281 | 0.160 |
Why?
|
| Acclimatization | 1 | 2018 | 40 | 0.160 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 15280 | 0.160 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 362 | 0.150 |
Why?
|
| ErbB Receptors | 5 | 2023 | 2376 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 2442 | 0.150 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 235 | 0.150 |
Why?
|
| Retrospective Studies | 14 | 2023 | 39982 | 0.150 |
Why?
|
| Receptors, Opioid, mu | 2 | 2016 | 96 | 0.150 |
Why?
|
| Injections, Intravenous | 5 | 2018 | 590 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 382 | 0.150 |
Why?
|
| Pyrazines | 1 | 2021 | 511 | 0.150 |
Why?
|
| Forecasting | 1 | 2000 | 699 | 0.150 |
Why?
|
| Capecitabine | 1 | 2018 | 391 | 0.140 |
Why?
|
| Hepatic Artery | 1 | 2018 | 255 | 0.140 |
Why?
|
| Antioxidants | 2 | 2011 | 519 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2009 | 4971 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 191 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2021 | 694 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2024 | 5417 | 0.140 |
Why?
|
| Maxillary Neoplasms | 1 | 1996 | 23 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 617 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 242 | 0.140 |
Why?
|
| Pulmonary Artery | 1 | 2000 | 520 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2003 | 1388 | 0.140 |
Why?
|
| Albumins | 1 | 2018 | 263 | 0.140 |
Why?
|
| Water | 1 | 2018 | 386 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 794 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 2051 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2002 | 898 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2017 | 862 | 0.130 |
Why?
|
| Prostatic Neoplasms | 4 | 2021 | 5870 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 4396 | 0.130 |
Why?
|
| Psychometrics | 1 | 2020 | 975 | 0.130 |
Why?
|
| Indazoles | 4 | 2020 | 310 | 0.120 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2021 | 165 | 0.120 |
Why?
|
| Exosomes | 1 | 2017 | 255 | 0.120 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 10268 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2000 | 1260 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1610 | 0.120 |
Why?
|
| Hypertension | 1 | 2024 | 1584 | 0.120 |
Why?
|
| Survival Rate | 12 | 2020 | 12535 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 155 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 1007 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 5146 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2021 | 1551 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 742 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 1997 | 489 | 0.110 |
Why?
|
| Dasatinib | 1 | 2017 | 881 | 0.110 |
Why?
|
| Piperidines | 2 | 2021 | 1098 | 0.110 |
Why?
|
| Pyridines | 1 | 2021 | 1312 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 732 | 0.110 |
Why?
|
| Combined Modality Therapy | 15 | 2016 | 9054 | 0.110 |
Why?
|
| Incidence | 4 | 2017 | 5824 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 7 | 2021 | 4148 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 1704 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2177 | 0.110 |
Why?
|
| Animals | 8 | 2024 | 61362 | 0.110 |
Why?
|
| Alopecia | 1 | 2013 | 125 | 0.110 |
Why?
|
| Etoposide | 4 | 2010 | 908 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2013 | 2575 | 0.110 |
Why?
|
| ras Proteins | 1 | 2017 | 804 | 0.110 |
Why?
|
| Stomach Neoplasms | 2 | 2023 | 2339 | 0.100 |
Why?
|
| Prospective Studies | 10 | 2023 | 13422 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2021 | 7789 | 0.100 |
Why?
|
| Imatinib Mesylate | 1 | 2017 | 1691 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2018 | 1389 | 0.100 |
Why?
|
| Superantigens | 1 | 1992 | 31 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 454 | 0.100 |
Why?
|
| Mass Screening | 1 | 2000 | 1547 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 972 | 0.100 |
Why?
|
| Enterotoxins | 1 | 1992 | 110 | 0.100 |
Why?
|
| Metformin | 1 | 2016 | 397 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 1485 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1249 | 0.100 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 186 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 666 | 0.100 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 1991 | 84 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2124 | 0.090 |
Why?
|
| Diarrhea | 3 | 2023 | 722 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 2 | 2005 | 368 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 682 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 924 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 5099 | 0.090 |
Why?
|
| Bacterial Toxins | 1 | 1992 | 218 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2017 | 3147 | 0.090 |
Why?
|
| Oncogene Proteins | 2 | 2022 | 366 | 0.090 |
Why?
|
| Time Factors | 5 | 2021 | 12979 | 0.090 |
Why?
|
| Cyclin E | 2 | 2022 | 284 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 4843 | 0.090 |
Why?
|
| Hypotension | 2 | 2003 | 225 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 2674 | 0.090 |
Why?
|
| Leukemia, Myeloid | 3 | 1985 | 993 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1011 | 0.080 |
Why?
|
| Patient Selection | 3 | 2021 | 2032 | 0.080 |
Why?
|
| Adolescent | 13 | 2023 | 32698 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2024 | 1061 | 0.080 |
Why?
|
| Disease Progression | 5 | 2021 | 6881 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2009 | 120 | 0.080 |
Why?
|
| Conjunctivitis | 1 | 1987 | 29 | 0.070 |
Why?
|
| United States | 5 | 2023 | 15834 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2009 | 476 | 0.070 |
Why?
|
| Hearing Disorders | 1 | 1987 | 34 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 566 | 0.070 |
Why?
|
| Physical Examination | 1 | 2009 | 306 | 0.070 |
Why?
|
| Drug Therapy, Combination | 4 | 2009 | 2344 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2018 | 1592 | 0.070 |
Why?
|
| Cerebellar Diseases | 1 | 1987 | 89 | 0.070 |
Why?
|
| Research | 1 | 2009 | 421 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2009 | 329 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 16246 | 0.070 |
Why?
|
| Isotretinoin | 2 | 2001 | 161 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1996 | 1860 | 0.070 |
Why?
|
| Texas | 4 | 2020 | 6445 | 0.070 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2016 | 66 | 0.070 |
Why?
|
| Risk Factors | 7 | 2021 | 17867 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2001 | 1858 | 0.060 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 879 | 0.060 |
Why?
|
| DNA, Neoplasm | 3 | 2005 | 1958 | 0.060 |
Why?
|
| Ditiocarb | 1 | 1995 | 4 | 0.060 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2010 | 417 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 3706 | 0.060 |
Why?
|
| Carmustine | 1 | 1985 | 225 | 0.060 |
Why?
|
| Syk Kinase | 1 | 2024 | 65 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2024 | 7647 | 0.060 |
Why?
|
| Hedgehogs | 1 | 1983 | 3 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2021 | 6766 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2006 | 727 | 0.060 |
Why?
|
| Research Design | 2 | 2009 | 1562 | 0.060 |
Why?
|
| Animals, Zoo | 1 | 1983 | 23 | 0.060 |
Why?
|
| Mycobacterium Infections | 1 | 1983 | 49 | 0.060 |
Why?
|
| Amifostine | 1 | 2003 | 99 | 0.050 |
Why?
|
| Genes, erbB | 1 | 2023 | 27 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1033 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5264 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2009 | 2033 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 508 | 0.050 |
Why?
|
| Infusions, Intravenous | 4 | 2016 | 1435 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 7274 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 503 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 1993 | 286 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 272 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2002 | 24 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2003 | 233 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2009 | 800 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 1985 | 580 | 0.050 |
Why?
|
| Transfusion Reaction | 1 | 1982 | 101 | 0.050 |
Why?
|
| Fluorouracil | 5 | 2002 | 1989 | 0.050 |
Why?
|
| Granulocytes | 1 | 1982 | 244 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 271 | 0.050 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Cytarabine | 1 | 1987 | 2015 | 0.050 |
Why?
|
| Leukapheresis | 1 | 1981 | 166 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 78 | 0.050 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 38 | 0.050 |
Why?
|
| Dexamethasone | 1 | 1986 | 1525 | 0.050 |
Why?
|
| Stroke | 1 | 2009 | 1061 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 400 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2009 | 1464 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.040 |
Why?
|
| Topotecan | 1 | 2021 | 248 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 221 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 170 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 317 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 4054 | 0.040 |
Why?
|
| Aspirin | 1 | 2003 | 373 | 0.040 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2021 | 169 | 0.040 |
Why?
|
| Income | 1 | 2021 | 232 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 457 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 529 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 542 | 0.040 |
Why?
|
| Smoking | 4 | 2005 | 2549 | 0.040 |
Why?
|
| Mice | 5 | 2023 | 35420 | 0.040 |
Why?
|
| Atmosphere | 1 | 2018 | 4 | 0.040 |
Why?
|
| Wood | 1 | 2018 | 18 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2017 | 1692 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 984 | 0.040 |
Why?
|
| Genomics | 2 | 2023 | 2834 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 437 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5050 | 0.040 |
Why?
|
| Plant Leaves | 1 | 2018 | 60 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2018 | 174 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14885 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 1623 | 0.040 |
Why?
|
| Echinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 854 | 0.040 |
Why?
|
| Trimetrexate | 1 | 1998 | 12 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 3205 | 0.040 |
Why?
|
| Climate Change | 1 | 2018 | 40 | 0.040 |
Why?
|
| Lung Diseases | 2 | 1994 | 750 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 1981 | 343 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 5157 | 0.040 |
Why?
|
| Immunoglobulin E | 2 | 2016 | 178 | 0.040 |
Why?
|
| Adenoma | 1 | 2003 | 738 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2312 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 506 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 743 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5924 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 224 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 536 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 4966 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 35 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 59 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2000 | 482 | 0.040 |
Why?
|
| Vitamin A | 1 | 1997 | 90 | 0.040 |
Why?
|
| Retinoids | 1 | 1997 | 152 | 0.030 |
Why?
|
| Laxatives | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2009 | 7233 | 0.030 |
Why?
|
| Carotenoids | 1 | 1997 | 104 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 174 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 650 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 245 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 6193 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2000 | 906 | 0.030 |
Why?
|
| Laryngectomy | 2 | 1991 | 244 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 626 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 326 | 0.030 |
Why?
|
| Registries | 2 | 2017 | 2212 | 0.030 |
Why?
|
| Lung | 3 | 2016 | 3287 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 115 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 135 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9464 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 1837 | 0.030 |
Why?
|
| Remission Induction | 4 | 1998 | 3658 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 223 | 0.030 |
Why?
|
| Tongue | 1 | 1995 | 86 | 0.030 |
Why?
|
| Hospice Care | 1 | 2016 | 163 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2017 | 12036 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 124 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2360 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2021 | 1555 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 449 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 7055 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 688 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 741 | 0.030 |
Why?
|
| Prostatitis | 1 | 1994 | 18 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 368 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1701 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 2112 | 0.030 |
Why?
|
| Back Pain | 1 | 1994 | 62 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 375 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 474 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1993 | 44 | 0.030 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1994 | 49 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 1998 | 2985 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 679 | 0.030 |
Why?
|
| Risk | 2 | 2011 | 1931 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1420 | 0.030 |
Why?
|
| Thiobarbiturates | 1 | 1993 | 3 | 0.030 |
Why?
|
| Anthraquinones | 1 | 1993 | 28 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 654 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 1388 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 378 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 809 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1996 | 639 | 0.030 |
Why?
|
| Biopsy | 1 | 2000 | 3490 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1996 | 889 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1828 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1994 | 298 | 0.030 |
Why?
|
| Ureteral Obstruction | 1 | 1994 | 141 | 0.030 |
Why?
|
| Transfection | 2 | 2002 | 3109 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 1557 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 770 | 0.030 |
Why?
|
| Placebos | 2 | 2001 | 439 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 526 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 4878 | 0.020 |
Why?
|
| Myocarditis | 1 | 1993 | 177 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 907 | 0.020 |
Why?
|
| Drug Evaluation | 3 | 1991 | 432 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1195 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1996 | 1169 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1998 | 1347 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1044 | 0.020 |
Why?
|
| Adenocarcinoma | 4 | 2007 | 7920 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1096 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 4839 | 0.020 |
Why?
|
| Nurse Clinicians | 1 | 1990 | 5 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Acute Disease | 2 | 1989 | 2492 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 800 | 0.020 |
Why?
|
| Anticoagulants | 2 | 1990 | 777 | 0.020 |
Why?
|
| Point Mutation | 1 | 1994 | 785 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1994 | 290 | 0.020 |
Why?
|
| Genes, ras | 1 | 1993 | 678 | 0.020 |
Why?
|
| Neck Dissection | 1 | 1991 | 294 | 0.020 |
Why?
|
| Hormone Antagonists | 1 | 2010 | 115 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3040 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 254 | 0.020 |
Why?
|
| Bleomycin | 1 | 1991 | 482 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 1990 | 52 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2050 | 0.020 |
Why?
|
| Pilot Projects | 2 | 1998 | 2855 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1994 | 1140 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 796 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1994 | 1057 | 0.020 |
Why?
|
| Selenomethionine | 1 | 2008 | 40 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4495 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 80 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1656 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 757 | 0.020 |
Why?
|
| Cause of Death | 1 | 1991 | 782 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 1216 | 0.020 |
Why?
|
| Leucovorin | 2 | 2002 | 345 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 333 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1345 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 2657 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 496 | 0.020 |
Why?
|
| Metalloporphyrins | 1 | 2007 | 31 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 1503 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 658 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 2804 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 540 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 747 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 726 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 886 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 557 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1127 | 0.020 |
Why?
|
| Glioma | 1 | 1998 | 1986 | 0.020 |
Why?
|
| Prochlorperazine | 1 | 1986 | 7 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 3061 | 0.020 |
Why?
|
| Metoclopramide | 1 | 1986 | 34 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 1467 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1990 | 592 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2005 | 22 | 0.020 |
Why?
|
| Prednisone | 2 | 1986 | 1034 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1994 | 1240 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2005 | 47 | 0.020 |
Why?
|
| Warfarin | 2 | 1990 | 145 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 72 | 0.020 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 1 | 1985 | 13 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1986 | 200 | 0.020 |
Why?
|
| Freezing | 1 | 1985 | 62 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2005 | 63 | 0.020 |
Why?
|
| Insulin | 1 | 2010 | 1424 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2006 | 218 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 626 | 0.020 |
Why?
|
| Blood Preservation | 1 | 1985 | 60 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 222 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1985 | 55 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 2003 | 4320 | 0.010 |
Why?
|
| Thrombosis | 1 | 1990 | 743 | 0.010 |
Why?
|
| Cell Line | 1 | 1992 | 5313 | 0.010 |
Why?
|
| Anemia | 1 | 2010 | 725 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1985 | 149 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 441 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1983 | 60 | 0.010 |
Why?
|
| Dermatitis | 1 | 1983 | 63 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2003 | 129 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1985 | 246 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 622 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1996 | 3241 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 9047 | 0.010 |
Why?
|
| Agglutination | 1 | 1982 | 6 | 0.010 |
Why?
|
| Granuloma | 1 | 1983 | 151 | 0.010 |
Why?
|
| Zinc Sulfate | 1 | 2002 | 7 | 0.010 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 1982 | 8 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1985 | 411 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 312 | 0.010 |
Why?
|
| Leukocytosis | 1 | 1981 | 122 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1981 | 132 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1982 | 301 | 0.010 |
Why?
|
| Colonic Polyps | 1 | 2003 | 228 | 0.010 |
Why?
|
| Thymidine | 1 | 1980 | 167 | 0.010 |
Why?
|
| Thromboembolism | 1 | 1981 | 150 | 0.010 |
Why?
|
| Emergencies | 1 | 1981 | 224 | 0.010 |
Why?
|
| Survivors | 1 | 2005 | 1021 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1985 | 2076 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2000 | 358 | 0.010 |
Why?
|
| Vinblastine | 1 | 2000 | 462 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1987 | 914 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2003 | 524 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 1282 | 0.010 |
Why?
|
| Heparin | 1 | 1981 | 343 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 194 | 0.010 |
Why?
|
| Procarbazine | 1 | 1998 | 71 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 1998 | 32 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1982 | 510 | 0.010 |
Why?
|
| Vincristine | 2 | 1998 | 1583 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1127 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1555 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 1902 | 0.010 |
Why?
|
| Lymphatic Metastasis | 3 | 1993 | 4969 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1992 | 1715 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2001 | 1042 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 1981 | 730 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 2087 | 0.010 |
Why?
|
| Fetal Proteins | 1 | 1976 | 27 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1996 | 184 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1976 | 127 | 0.010 |
Why?
|
| Astrocytoma | 1 | 1998 | 325 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2001 | 1582 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1976 | 256 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 5759 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1995 | 205 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1998 | 957 | 0.010 |
Why?
|
| Necrosis | 1 | 1995 | 591 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1993 | 291 | 0.010 |
Why?
|
| Morbidity | 1 | 1994 | 397 | 0.010 |
Why?
|
| Bias | 1 | 1993 | 210 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1976 | 346 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 4993 | 0.010 |
Why?
|
| Hemorrhage | 2 | 1990 | 724 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 6344 | 0.010 |
Why?
|
| Lymphoma | 1 | 1980 | 1516 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 1489 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 5415 | 0.010 |
Why?
|
| Leukemia | 1 | 1980 | 1719 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1991 | 233 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 4102 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1994 | 359 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1994 | 675 | 0.010 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1990 | 15 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 709 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 1992 | 555 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1990 | 261 | 0.010 |
Why?
|
| Prostate | 1 | 1994 | 1090 | 0.000 |
Why?
|
| Odds Ratio | 1 | 1993 | 2300 | 0.000 |
Why?
|
| Immunophenotyping | 1 | 1992 | 1724 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1993 | 1146 | 0.000 |
Why?
|
| Methotrexate | 1 | 1991 | 1025 | 0.000 |
Why?
|
| Apoptosis | 1 | 2002 | 7757 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1998 | 1781 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1992 | 1571 | 0.000 |
Why?
|
| Base Sequence | 1 | 1994 | 5406 | 0.000 |
Why?
|
| Mediastinoscopy | 1 | 1986 | 33 | 0.000 |
Why?
|
| Lymphography | 1 | 1986 | 51 | 0.000 |
Why?
|
| Alleles | 1 | 1993 | 2598 | 0.000 |
Why?
|
| Heart | 1 | 1993 | 1173 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 6639 | 0.000 |
Why?
|
| Patient Compliance | 1 | 1990 | 677 | 0.000 |
Why?
|
| Infant | 1 | 1982 | 14003 | 0.000 |
Why?
|
| Atrial Fibrillation | 1 | 1993 | 727 | 0.000 |
Why?
|
| Immunoelectrophoresis, Two-Dimensional | 1 | 1985 | 3 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1985 | 261 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1993 | 3328 | 0.000 |
Why?
|
| Genotype | 1 | 1993 | 4249 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1982 | 17083 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1985 | 202 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1993 | 6234 | 0.000 |
Why?
|
| Quality of Life | 1 | 1998 | 4810 | 0.000 |
Why?
|
| Child | 2 | 1982 | 30572 | 0.000 |
Why?
|
| Megakaryocytes | 1 | 1983 | 128 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1983 | 304 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 336 | 0.000 |
Why?
|
| Karyotyping | 1 | 1983 | 1064 | 0.000 |
Why?
|
| Leukocytes | 1 | 1983 | 420 | 0.000 |
Why?
|
| Thymidine Phosphorylase | 1 | 1980 | 26 | 0.000 |
Why?
|
| Hepatomegaly | 1 | 1980 | 71 | 0.000 |
Why?
|
| Thymine | 1 | 1980 | 45 | 0.000 |
Why?
|
| Patient Care Planning | 1 | 1981 | 301 | 0.000 |
Why?
|
| Thymidine Kinase | 1 | 1980 | 223 | 0.000 |
Why?
|
| Splenomegaly | 1 | 1980 | 172 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1980 | 727 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1981 | 342 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1983 | 1273 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1981 | 342 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1977 | 125 | 0.000 |
Why?
|
| Dysgerminoma | 1 | 1976 | 42 | 0.000 |
Why?
|
| Choriocarcinoma | 1 | 1976 | 49 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1983 | 1581 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1981 | 824 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1983 | 2454 | 0.000 |
Why?
|
| Teratoma | 1 | 1976 | 248 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1980 | 1362 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1980 | 2440 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1976 | 560 | 0.000 |
Why?
|
| Phenotype | 1 | 1983 | 6503 | 0.000 |
Why?
|
| Peritoneal Neoplasms | 1 | 1976 | 866 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1980 | 3946 | 0.000 |
Why?
|